SANUWAVE Health, Inc. (OTCMKTS:SNWV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
On June 26, 2018, SANUWAVE Health, Inc., a Nevada Corporation (the “Company”), announced that the Company had entered into an agreement (the “Agreement”) with Johnfk Medical Inc. (“FKS”), effective as of June 14, 2018, to which the Company and FKS will enter into a joint venture for the manufacture, sale and distribution of the Company’s dermaPACE® and orthoPACE® devices. The Agreement provides that the parties will work together to enter into a definitive agreement over the next five months.
Under the Agreement, FKS paid the Company an initial distribution rights fee in Taiwan on June 22, 2018 in the amount of $500,000, with an additional initial distribution rights fee in Singapore, Malaysia, Brunie, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines and Vietnam (the “SEA Region”) in the third quarter of 2018 in the amount of $500,000.
The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Agreement, dated June 14, 2018, by and among the Company and Johnfk Medical Inc.
SANUWAVE Health, Inc. ExhibitEX-10.1 2 snwv_ex101.htm AGREEMENT Blueprint Exhibit 10.1 Johnfk Medical Inc. 916 Zhongzheng road,…To view the full exhibit click
About SANUWAVE Health, Inc. (OTCMKTS:SNWV)
SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.